March 11, 2024
by Andrii Buvailo, PhD
News
Recursion (NASDAQ: RXRX), a clinical-stage TechBio company, has unveiled plans to establish a new office in London's King’s Cross area, …
March 5, 2024
by Andrii Buvailo, PhD
News
Elsevier, a global provider of information and analytics in science and health with 140 years of history, has entered into …
March 4, 2024
by BiopharmaTrend
News
Lantern Pharma, a NASDAQ-listed company specializing in AI-driven cancer drug discovery and development, has announced a milestone with its artificial intelligence platform …
Feb. 28, 2024
by Andrii Buvailo, PhD
News
It is a remarkable day for Ginkgo Bioworks, a notable player in the field of synthetic biology, as the company …
Feb. 13, 2024
by Dana Sokolova
Biopharma insight
The biotech and pharmaceutical industries are entering 2024 amid a wave of innovation and technological advancement. The biopharma field is …
Feb. 11, 2024
by Natalia Honchar
Biopharma insight
According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences …
Feb. 7, 2024
by Roman Kasianov
News
Exscientia plc, a UK-based AI-driven precision medicine company, has initiated a clinical study, EXCYTE-2, focusing on acute myeloid leukaemia (AML) patients. …
Feb. 6, 2024
by Andrii Buvailo, PhD
Interview
As we stand at the crossroads of artificial intelligence (AI) and biotech, what future awaits protein design, and how are …
Feb. 2, 2024
by News Team
News
Aqemia, a Paris-based biotech startup, raised an additional €30 million in a Series A funding extension, totaling €60 million in …
Jan. 26, 2024
by Natalia Honchar
Biopharma insight
When we hear “AI in drug discovery”, there is a high chance our imagination would draw a small molecule discovery …
Jan. 26, 2024
by Andrii Buvailo, PhD
Biopharma insight
The year 2024 has ushered in a new wave of excitement in the biotech industry, with several promising companies making …
Jan. 23, 2024
by Andrii Buvailo
Interview
The development of oncology drugs faces significant challenges, including a high failure rate (97%) in clinical trials, due to complex …